tazemetostat + HMPL-689

**Tazemetostat + HMPL-689** is an investigational combination therapy used for the treatment of relapsed or refractory lymphoma, including aggressive non-Hodgkin lymphoma and B-cell lymphoma subtypes[1][3][7]. Tazemetostat is a selective small molecule inhibitor of the enhancer-of-zeste-homolog-2 (EZH2), an epigenetic regulator implicated in cancer cell proliferation[7]. HMPL-689, also known as amdizalisib, is a potent and highly selective small molecule inhibitor of phosphoinositide 3-kinase delta (PI3Kδ), a kinase involved in B-cell receptor signaling and the survival of malignant lymphocytes[2][4][7]. Preclinical data demonstrated synergistic anti-tumor effects for the combination, while early clinical results show promising efficacy and a manageable safety profile in lymphoma patients[7].

Other names

ezh2 inhibitor + PI3Kδ inhibitortazemetostat plus amdizalisib